742.91
price up icon0.69%   5.08
after-market 시간 외 거래: 742.05 -0.86 -0.12%
loading
전일 마감가:
$737.83
열려 있는:
$736.315
하루 거래량:
2.42M
Relative Volume:
0.56
시가총액:
$703.13B
수익:
$53.26B
순이익/손실:
$13.80B
주가수익비율:
48.56
EPS:
15.3
순현금흐름:
$-50.20M
1주 성능:
+1.50%
1개월 성능:
-3.39%
6개월 성능:
-18.46%
1년 성능:
-21.49%
1일 변동 폭
Value
$735.33
$747.00
1주일 범위
Value
$723.64
$747.00
52주 변동 폭
Value
$623.78
$943.00

일라이 릴리 Stock (LLY) Company Profile

Name
명칭
Lilly Eli Co
Name
전화
(317) 276-2000
Name
주소
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Name
직원
47,000
Name
트위터
@LillyPad
Name
다음 수익 날짜
2024-10-30
Name
최신 SEC 제출 서류
Name
LLY's Discussions on Twitter

LLY을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Drug Manufacturers - General icon
LLY
Lilly Eli Co
742.91 659.07B 53.26B 13.80B -50.20M 15.30
Drug Manufacturers - General icon
JNJ
Johnson Johnson
178.76 428.83B 90.62B 22.66B 18.18B 9.35
Drug Manufacturers - General icon
ABBV
Abbvie Inc
213.00 374.37B 58.33B 3.73B 18.24B 2.10
Drug Manufacturers - General icon
NVS
Novartis Ag Adr
128.42 245.16B 53.40B 13.68B 16.89B 6.9231
Drug Manufacturers - General icon
MRK
Merck Co Inc
84.05 213.51B 63.43B 16.42B 14.72B 6.49

일라이 릴리 Stock (LLY) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2025-08-27 업그레이드 HSBC Securities Reduce → Hold
2025-08-18 다운그레이드 Daiwa Securities Outperform → Neutral
2025-08-07 다운그레이드 Leerink Partners Outperform → Market Perform
2025-06-05 다운그레이드 Erste Group Buy → Hold
2025-04-28 다운그레이드 HSBC Securities Buy → Reduce
2025-04-22 개시 Cantor Fitzgerald Overweight
2024-12-10 재개 BofA Securities Buy
2024-11-15 개시 Wolfe Research Outperform
2024-10-17 개시 Bernstein Outperform
2024-09-13 재개 Citigroup Buy
2024-08-12 업그레이드 Deutsche Bank Hold → Buy
2024-02-21 다운그레이드 DZ Bank Buy → Hold
2024-02-16 재확인 Morgan Stanley Overweight
2023-12-21 다운그레이드 Daiwa Securities Buy → Outperform
2023-11-09 개시 Deutsche Bank Hold
2023-10-20 재개 UBS Buy
2023-08-09 업그레이드 Jefferies Hold → Buy
2023-07-26 재확인 Citigroup Buy
2023-07-14 개시 HSBC Securities Buy
2023-05-24 재확인 BofA Securities Buy
2023-05-24 재확인 UBS Buy
2023-03-13 업그레이드 Wells Fargo Equal Weight → Overweight
2023-03-06 개시 Jefferies Hold
2023-02-15 다운그레이드 Societe Generale Hold → Sell
2022-11-18 개시 Credit Suisse Outperform
2022-09-22 업그레이드 UBS Neutral → Buy
2022-05-23 개시 SVB Leerink Outperform
2022-04-06 재개 Morgan Stanley Overweight
2022-03-10 개시 Daiwa Securities Outperform
2022-01-21 업그레이드 DZ Bank Hold → Buy
2022-01-03 재확인 Bernstein Mkt Perform
2021-12-17 개시 Goldman Neutral
2021-12-16 재확인 BMO Capital Markets Outperform
2021-12-16 재확인 BofA Securities Buy
2021-12-09 재개 Wells Fargo Equal Weight
2021-11-19 개시 BMO Capital Markets Outperform
2021-10-11 업그레이드 Berenberg Hold → Buy
2021-09-29 업그레이드 Citigroup Neutral → Buy
2021-08-05 업그레이드 DZ Bank Hold → Buy
2021-07-27 재개 Truist Buy
2021-06-24 재확인 Cantor Fitzgerald Overweight
2021-01-19 업그레이드 Mizuho Neutral → Buy
2020-12-10 업그레이드 Wolfe Research Peer Perform → Outperform
2020-11-10 재개 Bernstein Mkt Perform
2020-09-29 개시 Berenberg Hold
2020-09-03 업그레이드 Morgan Stanley Equal-Weight → Overweight
2020-06-16 업그레이드 Guggenheim Neutral → Buy
2020-04-21 다운그레이드 UBS Buy → Neutral
2020-04-09 다운그레이드 Morgan Stanley Overweight → Equal-Weight
2020-02-06 개시 Mizuho Neutral
2019-12-18 업그레이드 Morgan Stanley Equal-Weight → Overweight
2019-10-17 재개 BofA/Merrill Buy
2019-05-28 개시 Goldman Buy
2019-04-24 업그레이드 Edward Jones Hold → Buy
2019-04-11 다운그레이드 Guggenheim Buy → Neutral
2019-03-12 개시 JP Morgan Overweight
2019-01-23 개시 UBS Buy
2018-11-26 다운그레이드 Citigroup Buy → Neutral
2018-10-31 업그레이드 Credit Suisse Underperform → Neutral
2018-10-09 개시 Guggenheim Buy
2018-10-01 재확인 SunTrust Buy
2018-09-26 재개 JP Morgan Overweight
모두보기

일라이 릴리 주식(LLY)의 최신 뉴스

pulisher
Sep 03, 2025

Hims & Hers gains after court rejects Eli Lilly’s case against Willow - Yahoo Finance

Sep 03, 2025
pulisher
Sep 03, 2025

BMO Capital Markets Reaffirms ‘Buy Rating’ on Eli Lilly Stock (LLY) - TipRanks

Sep 03, 2025
pulisher
Sep 03, 2025

Gastric Cancer Pipeline 2025: Latest FDA Approvals, Clinical Trials, and Emerging Therapies Assessment by DelveInsight | Eli Lilly and Company, BeiGene, Hutchison MediPharma, Astellas Pharma, Henlix - Barchart.com

Sep 03, 2025
pulisher
Sep 03, 2025

PRESSR: Lilly's oral GLP-1, orforglipron, is successful in third Phase 3 trial, triggering global regulatory submissions this year for the treatment of obesity - TradingView

Sep 03, 2025
pulisher
Sep 03, 2025

Is Novo Nordisk Stock a Buy Now? - The Motley Fool

Sep 03, 2025
pulisher
Sep 03, 2025

Stomach Cancer Treatment Market Review 2020-2024 and Forecast 2025-2030 - GlobeNewswire Inc.

Sep 03, 2025
pulisher
Sep 02, 2025

Fueled by Lilly's Lebanon investment, local builds future in biotech at Ivy Tech - reporter.net

Sep 02, 2025
pulisher
Sep 02, 2025

Analyst Forecasts $25 Billion of Annual Sales for Eli Lilly’s (LLY) New Weight-Loss Pill - TipRanks

Sep 02, 2025
pulisher
Sep 02, 2025

Eli Lilly's once-daily obesity pill passes phase 3 trials - 조선일보

Sep 02, 2025
pulisher
Sep 02, 2025

BMO Capital Affirms Eli Lilly (LLY)’s ‘Outperform’ Rating on Weight Loss Drug Prospects - Yahoo Finance

Sep 02, 2025
pulisher
Sep 02, 2025

Eli Lilly's New Drugs Beyond Mounjaro And Zepbound Boost Sales - Barchart.com

Sep 02, 2025
pulisher
Sep 02, 2025

Eli Lilly's New Drugs Beyond Mounjaro and Zepbound Boost Sales - Nasdaq

Sep 02, 2025
pulisher
Sep 02, 2025

What's Going On With Novo Nordisk Stock Tuesday?Novo Nordisk (NYSE:NVO), Eli Lilly (NYSE:LLY) - Benzinga

Sep 02, 2025
pulisher
Sep 02, 2025

Eyes on Asia: Lilly, Fosun, RemeGene - BioXconomy

Sep 02, 2025
pulisher
Sep 02, 2025

Lilly Ends Two Mid-Stage Trials for Second Obesity Asset - BioSpace

Sep 02, 2025
pulisher
Sep 02, 2025

Is Eli Lilly and Company’s growth already priced inJuly 2025 Decliners & Fast Moving Stock Watchlists - خودرو بانک

Sep 02, 2025
pulisher
Sep 02, 2025

Eli Lilly & Co: Strong Buy Rating Driven by Promising Weight Loss Drug and Innovative Subscription Model - TipRanks

Sep 02, 2025
pulisher
Sep 02, 2025

Recently, Eli Lilly's obesity treatment "Munzaro" has been released in Korea and interest in obesity.. - 매일경제

Sep 02, 2025
pulisher
Sep 02, 2025

Recently, Eli Lilly's obesity treatment Maunzaro was released in Korea, and as interest in obesity t.. - 매일경제

Sep 02, 2025
pulisher
Sep 02, 2025

Eli Lilly and Company (LLY) Halts UK Mounjaro Shipments Ahead of Planned Price Increase - uk.finance.yahoo.com

Sep 02, 2025
pulisher
Sep 01, 2025

Can trapped investors hope for a rebound in Eli Lilly and CompanyTrade Performance Summary & Detailed Earnings Play Alerts - Newser

Sep 01, 2025
pulisher
Sep 01, 2025

Eli Lilly’s SWOT analysis: stock’s growth potential in obesity market faces challenges - Investing.com

Sep 01, 2025
pulisher
Sep 01, 2025

Eli Lilly (LLY) Partners with JD.com to Sell Weight-Loss Drugs in China - TipRanks

Sep 01, 2025
pulisher
Sep 01, 2025

ESC25: Novo's Wegovy slashes CV risk by 57% over Lilly's Zepbound in real-world study - FirstWord Pharma

Sep 01, 2025
pulisher
Sep 01, 2025

Novo Nordisk Says Wegovy Cuts Heart Risk by 57% Compared With Eli Lilly’s Obesity Drug - The Wall Street Journal

Sep 01, 2025
pulisher
Aug 31, 2025

Eli Lilly and Company Stock (LLY) Opinions on Orforglipron Trial Data | LLY Stock News - Quiver Quantitative

Aug 31, 2025
pulisher
Aug 31, 2025

Can you recover from losses in Eli Lilly and CompanyJuly 2025 Levels & Verified Chart Pattern Trade Signals - Newser

Aug 31, 2025
pulisher
Aug 31, 2025

HSBC Upgrades Eli Lilly (LLY) to Hold, Lifts Price Target to $700 - Yahoo Finance

Aug 31, 2025
pulisher
Aug 30, 2025

Intraday pattern recognizer results for Eli Lilly and CompanyPortfolio Risk Report & Fast Exit Strategy with Risk Control - Newser

Aug 30, 2025
pulisher
Aug 30, 2025

Benzinga Bulls And Bears: Eli Lilly, Firefly, Marvell — And Trump Investment Hints Boost Defense Stocks - inkl

Aug 30, 2025
pulisher
Aug 30, 2025

Eli Lilly is close to launching the strongest weight-loss drug ever. Somehow, gym bros are already taking it to shred fat. - Business Insider

Aug 30, 2025
pulisher
Aug 30, 2025

Eli Lilly and Company (LLY): A Bull Case Theory - MSN

Aug 30, 2025
pulisher
Aug 29, 2025

Sector ETF performance correlation with Eli Lilly and Company2025 Geopolitical Influence & Consistent Profit Trading Strategies - Newser

Aug 29, 2025
pulisher
Aug 29, 2025

Eli Lilly and Company (LLY) Needs To Get A Weight Loss Pill Out, Says Jim Cramer - Yahoo Finance

Aug 29, 2025
pulisher
Aug 29, 2025

Pharmaceutical Cos. Back Lilly In Mich. Insulin Pricing Probe - Law360

Aug 29, 2025
pulisher
Aug 29, 2025

Jim Cramer Sees Big Potential in Eli Lilly’s Weight-Loss and Diabetes Pill - Yahoo Finance

Aug 29, 2025
pulisher
Aug 29, 2025

The Zacks Analyst Blog Highlights Lilly, Oracle, Procter & Gamble and Comstock Holding Companies - ca.finance.yahoo.com

Aug 29, 2025
pulisher
Aug 29, 2025

Eli Lilly (NYSE:LLY) vs Novo Nordisk (NYSE:NVO): Growth Premium vs Value Upside - tradingnews.com

Aug 29, 2025
pulisher
Aug 29, 2025

Eli Lilly (NYSE:LLY) Stock Price Trading at $732 as GLP-1 Sales Surge and Drug Pricing Risks Rise - tradingnews.com

Aug 29, 2025
pulisher
Aug 29, 2025

Is Eli Lilly Stock A Buy As The Company Aims For Weight-Loss Pill Approval? - Investor's Business Daily

Aug 29, 2025
pulisher
Aug 29, 2025

Eli Lilly Stock: Is LLY Underperforming the Healthcare Sector? - Yahoo Finance

Aug 29, 2025
pulisher
Aug 29, 2025

Eli Lilly Temporarily Stops U.K. Shipments of Its Weight-Loss Drug - TipRanks

Aug 29, 2025
pulisher
Aug 29, 2025

Eli Lilly Partners with JD Health for Direct-to-Consumer Obesity and Diabetes Drug Sales - AInvest

Aug 29, 2025
pulisher
Aug 29, 2025

JD Health (06618.HK) has reached a strategic cooperation agreement with Eli Lilly and Co in China. - 富途牛牛

Aug 29, 2025
pulisher
Aug 29, 2025

LLY Stock Quote Price and Forecast - CNN

Aug 29, 2025
pulisher
Aug 29, 2025

Eli Lilly Partners With China Tech Giant for Obesity Drug Sales - Bloomberg

Aug 29, 2025
pulisher
Aug 29, 2025

Eli Lilly to offer UK discount on Mounjaro weight-loss jabs - The Independent

Aug 29, 2025
pulisher
Aug 28, 2025

Decoding Insider Activity at Eli Lilly: A Closer Look at Recent Share Sales and Buying Conviction - AInvest

Aug 28, 2025
pulisher
Aug 28, 2025

Top Stock Reports for Eli Lilly, Oracle & Procter & Gamble - Nasdaq

Aug 28, 2025
pulisher
Aug 28, 2025

Eli Lilly CIO Susan Ridlen retiring - Pensions & Investments

Aug 28, 2025
pulisher
Aug 28, 2025

Eli Lilly (LLY) technical analysisEli Lilly (NYSE:LLY) - Benzinga

Aug 28, 2025

일라이 릴리 (LLY) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
drug_manufacturers_general JNJ
$178.76
price up icon 0.43%
$213.00
price up icon 0.54%
drug_manufacturers_general NVS
$128.42
price up icon 0.15%
drug_manufacturers_general MRK
$84.05
price down icon 0.15%
drug_manufacturers_general NVO
$56.14
price down icon 1.06%
자본화:     |  볼륨(24시간):